Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Advaxis Inc (ADXS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 89,454
  • Shares Outstanding, K 52,620
  • Annual Sales, $ 12,030 K
  • Annual Income, $ -93,440 K
  • 36-Month Beta 1.40
  • Price/Sales 7.44
  • Price/Cash Flow N/A
  • Price/Book 1.97

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.62 +0.62%
on 06/22/18
1.96 -16.84%
on 06/11/18
-0.19 (-10.44%)
since 05/22/18
3-Month
1.51 +7.95%
on 04/03/18
2.04 -20.10%
on 05/15/18
-0.24 (-12.83%)
since 03/22/18
52-Week
1.51 +7.95%
on 04/03/18
7.45 -78.12%
on 09/11/17
-4.71 (-74.29%)
since 06/22/17

Most Recent Stories

More News
Advaxis Announces Dosing of First Patient with ADXS-NEO, an Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens

---First patient dosed is being treated for NSCLC

ADXS : 1.63 (-4.12%)
Complimentary Technical Snapshots on Adverum Biotechnologies and Three More Biotech Stocks

Stock Research Monitor: ADAP, ADRO, and ADXS

ADXS : 1.63 (-4.12%)
ADAP : 13.00 (-0.61%)
ADRO : 8.05 (+5.23%)
Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results

--Conference call begins today at 11:00 a.m. Eastern time

ADXS : 1.63 (-4.12%)
Advaxis Appoints Molly Henderson as Chief Financial Officer

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the appointment...

ADXS : 1.63 (-4.12%)
IOVA : 13.60 (+3.42%)
LBIO : 6.95 (-2.80%)
Data Highlighting Advaxis' ADXS-PSA Presented at ASCO Annual Meeting

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced preliminary data...

ADXS : 1.63 (-4.12%)
MRK : 61.47 (+0.47%)
Advaxis to Host Business Update and Second Quarter 2018 Financial Results Conference Call on June 7, 2018

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced today the upcoming...

ADXS : 1.63 (-4.12%)
Analysis: Positioning to Benefit within Advaxis, e.l.f. Beauty, Heron Therapeutics, PVH, Energy Recovery, and A. O. Smith -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Advaxis, Inc. (NASDAQ:ADXS),...

ADXS : 1.63 (-4.12%)
PVH : 152.08 (-1.50%)
AOS : 60.27 (+0.35%)
ERII : 8.12 (-0.25%)
ELF : 18.57 (-0.11%)
HRTX : 41.35 (+3.50%)
Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, provides an update on recently...

ADXS : 1.63 (-4.12%)
Advaxis Announces Executive Leadership Changes

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth...

ADXS : 1.63 (-4.12%)
Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of...

ADXS : 1.63 (-4.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade ADXS with:

Business Summary

Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence...

See More

Key Turning Points

2nd Resistance Point 1.77
1st Resistance Point 1.70
Last Price 1.63
1st Support Level 1.59
2nd Support Level 1.55

See More

52-Week High 7.45
Fibonacci 61.8% 5.18
Fibonacci 50% 4.48
Fibonacci 38.2% 3.78
Last Price 1.63
52-Week Low 1.51

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar